Where Sage Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Sage Therapeutics (NASDAQ:SAGE) has received mixed analyst ratings in the last quarter, with 1 bullish, 2 somewhat bullish, and 15 indifferent ratings. The average 12-month price target for the company is $30.28, a 44.69% decrease from the previous average of $54.75.
September 07, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mixed analyst ratings and a decreased price target could impact Sage Therapeutics' stock price.
Analyst ratings can significantly influence investor sentiment. The mixed ratings and decreased price target suggest a lack of confidence in the company's performance, which could negatively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100